NCT01490632 A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis Status COMPLETED Phase PHASE2
NCT01445769 Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis Status COMPLETED Phase PHASE2
NCT01398475 A Relative Bioavailability and Food Effect Study of New Formulations Status COMPLETED Phase PHASE1
NCT01375140 Ruxolitinib and Lenalidomide for Patients With Myelofibrosis Status COMPLETED Phase PHASE2
NCT01348490 Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF) Status COMPLETED Phase PHASE2
NCT01340651 Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients Status COMPLETED Phase PHASE2
NCT01317875 Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) Status COMPLETED Phase PHASE1
NCT01254136 Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer Status TERMINATED Phase PHASE1/PHASE2
NCT01247883 A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers Status COMPLETED Phase PHASE1
NCT01243944 Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) Status COMPLETED Phase PHASE3
NCT01195311 A Dose-escalation Study in Subjects With Advanced Malignancies Status COMPLETED Phase PHASE1
NCT01185353 A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy Status COMPLETED Phase PHASE2
NCT01072266 A Dose-escalation Study in Subjects With Advanced Malignancies Status COMPLETED Phase PHASE1
NCT00952289 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Status COMPLETED Phase PHASE3
NCT00902486 INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs Status COMPLETED Phase PHASE2
NCT00864175 Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer Status TERMINATED Phase PHASE1/PHASE2
NCT00820950 A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis Status COMPLETED Phase PHASE2